Picture loading failed.

Anti-IL2RA therapeutic antibody (Pre-made Camidanlumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Camidanlumab Tesirine (ADCT-301) is an antibody drug conjugate (ADC), composed of the human monoclonal antibody, HuMax-TAC, which is directed against human CD25. The antibody is conjugated through a protease cleavable linker to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxin.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-089-1mg 1mg 3090
GMP-Bios-ab-089-10mg 10mg 21890
GMP-Bios-ab-089-100mg 100mg 148000
GMP-Bios-ab-089-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL2RA therapeutic antibody (Pre-made Camidanlumab biosimilar,Whole mAb ADC)
INN Name Camidanlumab
TargetIL2RA
FormatWhole mAb ADC
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesADC Therapeutics;Genmab
Conditions Approvedna
Conditions ActiveHodgkin's disease;Non-Hodgkin's lymphoma;Solid tumours
Conditions DiscontinuedAcute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma
Development Techna